$5.68
-0.27 (-4.54%)
Open$5.85
Previous Close$5.95
Day High$5.95
Day Low$5.48
52W High$11.54
52W Low$4.50
Volume—
Avg Volume28.2K
Market Cap131.08M
P/E Ratio—
EPS$-1.17
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+476.9% upside
Current
$5.68
$5.68
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.34M | 16.36M | 16.49M |
| Net Income | -26,979,884 | -919,800 | -1,097,385 |
| Profit Margin | -202.2% | -5.6% | -6.7% |
| EBITDA | -29,444,559 | -1,433,447 | -1,263,705 |
| Free Cash Flow | — | -1,064,720 | -1,173,966 |
| Rev Growth | — | +3.8% | -10.0% |
| Debt/Equity | — | 1.22 | 1.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |